Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome Therapeutics (AXSM) is anticipated to report a quarterly loss of $1.05 per share and revenues of $140.15 million for the June 2025 quarter, marking a 15.3% improvement in EPS and a 60.8% increase in revenue year-over-year. Supported by a Zacks Earnings ESP of +3.87% and a Zacks Rank #3, the company is strongly positioned to surpass consensus EPS estimates, consistent with its record of beating expectations in the last four quarters. This makes AXSM a compelling candidate for an earnings beat, though investors are advised to consider other market factors.

Analysis

Axsome Therapeutics (AXSM) presents a compelling case for a potential earnings beat in its upcoming June 2025 quarterly report, underpinned by strong growth forecasts and positive analyst sentiment. Consensus estimates project a significant 60.8% year-over-year revenue increase to $140.15 million and a 15.3% improvement in profitability, with the expected loss per share narrowing to $1.05. Confidence in this outlook is reinforced by quantitative indicators; the consensus EPS estimate has been revised 1.06% higher in the last 30 days, and the Zacks Earnings ESP is a positive 3.87%. This combination, along with a Zacks Rank #3, historically correlates with a nearly 70% probability of a positive earnings surprise. This forward-looking optimism is consistent with the company's performance history, having surpassed consensus EPS estimates in the last four consecutive quarters, including a +36.51% surprise in the prior period. The company's strong position is further highlighted when contrasted with industry peer Apellis Pharmaceuticals (APLS), which faces expectations of a 5.3% revenue decline and holds a negative Earnings ESP, indicating a much weaker outlook.

Key Decisions for Investors

• Given the positive quantitative signals, including a +3.87% Earnings ESP and a history of four consecutive EPS beats, investors may consider Axsome a strong candidate for a positive earnings surprise on August 4th.
• While an earnings beat seems probable, the stock's post-release performance will heavily depend on management's forward guidance, making the subsequent earnings call a critical event to monitor for assessing the sustainability of any price movement.
• The fundamental outlook for Axsome appears significantly stronger than that of its peer Apellis Pharmaceuticals, suggesting that investors looking for exposure to the biomedical sector might consider overweighting AXSM relative to APLS based on these contrasting pre-earnings indicators.
• Investors should remain mindful of the inherent volatility in biopharmaceutical stocks around earnings events and size positions to account for potential sharp price swings, regardless of the headline earnings result.